nodes	percent_of_prediction	percent_of_DWPC	metapath
Ranolazine—CYP3A4—Ifosfamide—testicular cancer	0.0479	0.272	CbGbCtD
Ranolazine—CYP2D6—Vinblastine—testicular cancer	0.04	0.227	CbGbCtD
Ranolazine—CYP3A4—Vinblastine—testicular cancer	0.0254	0.144	CbGbCtD
Ranolazine—CYP2D6—Doxorubicin—testicular cancer	0.0245	0.139	CbGbCtD
Ranolazine—CYP3A4—Etoposide—testicular cancer	0.0229	0.13	CbGbCtD
Ranolazine—CYP3A4—Doxorubicin—testicular cancer	0.0156	0.0886	CbGbCtD
Ranolazine—Asthenia—Bleomycin—testicular cancer	0.00151	0.00184	CcSEcCtD
Ranolazine—Dehydration—Epirubicin—testicular cancer	0.00151	0.00183	CcSEcCtD
Ranolazine—Skin disorder—Cisplatin—testicular cancer	0.00151	0.00183	CcSEcCtD
Ranolazine—Diplopia—Doxorubicin—testicular cancer	0.0015	0.00182	CcSEcCtD
Ranolazine—Pain in extremity—Doxorubicin—testicular cancer	0.0015	0.00182	CcSEcCtD
Ranolazine—Hyperhidrosis—Cisplatin—testicular cancer	0.0015	0.00182	CcSEcCtD
Ranolazine—Pruritus—Bleomycin—testicular cancer	0.00149	0.00181	CcSEcCtD
Ranolazine—Feeling abnormal—Ifosfamide—testicular cancer	0.00148	0.0018	CcSEcCtD
Ranolazine—Eosinophilia—Methotrexate—testicular cancer	0.00148	0.0018	CcSEcCtD
Ranolazine—Nausea—Vinblastine—testicular cancer	0.00148	0.0018	CcSEcCtD
Ranolazine—Orthostatic hypotension—Epirubicin—testicular cancer	0.00148	0.0018	CcSEcCtD
Ranolazine—Anorexia—Cisplatin—testicular cancer	0.00148	0.0018	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00147	0.00179	CcSEcCtD
Ranolazine—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00147	0.00179	CcSEcCtD
Ranolazine—Pancreatitis—Methotrexate—testicular cancer	0.00147	0.00178	CcSEcCtD
Ranolazine—Breast disorder—Epirubicin—testicular cancer	0.00147	0.00178	CcSEcCtD
Ranolazine—Hypotension—Cisplatin—testicular cancer	0.00145	0.00176	CcSEcCtD
Ranolazine—Abdominal discomfort—Methotrexate—testicular cancer	0.00144	0.00174	CcSEcCtD
Ranolazine—Confusional state—Etoposide—testicular cancer	0.00143	0.00174	CcSEcCtD
Ranolazine—Urticaria—Ifosfamide—testicular cancer	0.00143	0.00174	CcSEcCtD
Ranolazine—Abdominal pain—Ifosfamide—testicular cancer	0.00142	0.00173	CcSEcCtD
Ranolazine—Pancytopenia—Methotrexate—testicular cancer	0.00142	0.00173	CcSEcCtD
Ranolazine—Asthenia—Dactinomycin—testicular cancer	0.00141	0.00171	CcSEcCtD
Ranolazine—Blood creatinine increased—Doxorubicin—testicular cancer	0.00141	0.00171	CcSEcCtD
Ranolazine—Dysuria—Methotrexate—testicular cancer	0.0014	0.0017	CcSEcCtD
Ranolazine—Dehydration—Doxorubicin—testicular cancer	0.0014	0.00169	CcSEcCtD
Ranolazine—Paraesthesia—Cisplatin—testicular cancer	0.00139	0.00169	CcSEcCtD
Ranolazine—Thrombocytopenia—Etoposide—testicular cancer	0.00139	0.00169	CcSEcCtD
Ranolazine—Eosinophilia—Epirubicin—testicular cancer	0.00139	0.00169	CcSEcCtD
Ranolazine—Dyspnoea—Cisplatin—testicular cancer	0.00138	0.00168	CcSEcCtD
Ranolazine—Skin disorder—Etoposide—testicular cancer	0.00138	0.00168	CcSEcCtD
Ranolazine—Erectile dysfunction—Methotrexate—testicular cancer	0.00138	0.00168	CcSEcCtD
Ranolazine—Hyperhidrosis—Etoposide—testicular cancer	0.00138	0.00167	CcSEcCtD
Ranolazine—Pancreatitis—Epirubicin—testicular cancer	0.00137	0.00167	CcSEcCtD
Ranolazine—Orthostatic hypotension—Doxorubicin—testicular cancer	0.00137	0.00166	CcSEcCtD
Ranolazine—Breast disorder—Doxorubicin—testicular cancer	0.00136	0.00165	CcSEcCtD
Ranolazine—Anorexia—Etoposide—testicular cancer	0.00136	0.00165	CcSEcCtD
Ranolazine—Decreased appetite—Cisplatin—testicular cancer	0.00135	0.00164	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00134	0.00163	CcSEcCtD
Ranolazine—Vomiting—Bleomycin—testicular cancer	0.00134	0.00163	CcSEcCtD
Ranolazine—Pancytopenia—Epirubicin—testicular cancer	0.00133	0.00162	CcSEcCtD
Ranolazine—Hypotension—Etoposide—testicular cancer	0.00133	0.00161	CcSEcCtD
Ranolazine—Rash—Bleomycin—testicular cancer	0.00133	0.00161	CcSEcCtD
Ranolazine—Dermatitis—Bleomycin—testicular cancer	0.00133	0.00161	CcSEcCtD
Ranolazine—Renal failure—Methotrexate—testicular cancer	0.00131	0.00159	CcSEcCtD
Ranolazine—Dysuria—Epirubicin—testicular cancer	0.00131	0.00159	CcSEcCtD
Ranolazine—Asthenia—Ifosfamide—testicular cancer	0.00129	0.00157	CcSEcCtD
Ranolazine—Eosinophilia—Doxorubicin—testicular cancer	0.00128	0.00156	CcSEcCtD
Ranolazine—Feeling abnormal—Cisplatin—testicular cancer	0.00128	0.00155	CcSEcCtD
Ranolazine—Paraesthesia—Etoposide—testicular cancer	0.00128	0.00155	CcSEcCtD
Ranolazine—Pruritus—Ifosfamide—testicular cancer	0.00127	0.00155	CcSEcCtD
Ranolazine—Haematuria—Methotrexate—testicular cancer	0.00127	0.00155	CcSEcCtD
Ranolazine—Pancreatitis—Doxorubicin—testicular cancer	0.00127	0.00154	CcSEcCtD
Ranolazine—Weight decreased—Epirubicin—testicular cancer	0.00127	0.00154	CcSEcCtD
Ranolazine—Dyspnoea—Etoposide—testicular cancer	0.00127	0.00154	CcSEcCtD
Ranolazine—Somnolence—Etoposide—testicular cancer	0.00126	0.00154	CcSEcCtD
Ranolazine—Epistaxis—Methotrexate—testicular cancer	0.00126	0.00153	CcSEcCtD
Ranolazine—Nausea—Bleomycin—testicular cancer	0.00125	0.00152	CcSEcCtD
Ranolazine—Vomiting—Dactinomycin—testicular cancer	0.00125	0.00152	CcSEcCtD
Ranolazine—Rash—Dactinomycin—testicular cancer	0.00124	0.0015	CcSEcCtD
Ranolazine—Decreased appetite—Etoposide—testicular cancer	0.00124	0.0015	CcSEcCtD
Ranolazine—Pancytopenia—Doxorubicin—testicular cancer	0.00123	0.0015	CcSEcCtD
Ranolazine—Renal failure—Epirubicin—testicular cancer	0.00123	0.00149	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Etoposide—testicular cancer	0.00123	0.00149	CcSEcCtD
Ranolazine—Fatigue—Etoposide—testicular cancer	0.00123	0.00149	CcSEcCtD
Ranolazine—Constipation—Etoposide—testicular cancer	0.00122	0.00148	CcSEcCtD
Ranolazine—Dysuria—Doxorubicin—testicular cancer	0.00121	0.00147	CcSEcCtD
Ranolazine—Haematuria—Epirubicin—testicular cancer	0.00119	0.00145	CcSEcCtD
Ranolazine—Dizziness—Ifosfamide—testicular cancer	0.00119	0.00145	CcSEcCtD
Ranolazine—Urinary tract disorder—Methotrexate—testicular cancer	0.00118	0.00144	CcSEcCtD
Ranolazine—Epistaxis—Epirubicin—testicular cancer	0.00118	0.00143	CcSEcCtD
Ranolazine—Urethral disorder—Methotrexate—testicular cancer	0.00118	0.00143	CcSEcCtD
Ranolazine—Weight decreased—Doxorubicin—testicular cancer	0.00117	0.00142	CcSEcCtD
Ranolazine—Feeling abnormal—Etoposide—testicular cancer	0.00117	0.00142	CcSEcCtD
Ranolazine—Nausea—Dactinomycin—testicular cancer	0.00117	0.00142	CcSEcCtD
Ranolazine—Gastrointestinal pain—Etoposide—testicular cancer	0.00116	0.00141	CcSEcCtD
Ranolazine—Visual impairment—Methotrexate—testicular cancer	0.00116	0.0014	CcSEcCtD
Ranolazine—Vomiting—Ifosfamide—testicular cancer	0.00115	0.00139	CcSEcCtD
Ranolazine—Bradycardia—Epirubicin—testicular cancer	0.00114	0.00139	CcSEcCtD
Ranolazine—Renal failure—Doxorubicin—testicular cancer	0.00114	0.00138	CcSEcCtD
Ranolazine—Rash—Ifosfamide—testicular cancer	0.00114	0.00138	CcSEcCtD
Ranolazine—Dermatitis—Ifosfamide—testicular cancer	0.00113	0.00138	CcSEcCtD
Ranolazine—Urticaria—Etoposide—testicular cancer	0.00113	0.00137	CcSEcCtD
Ranolazine—Abdominal pain—Etoposide—testicular cancer	0.00112	0.00137	CcSEcCtD
Ranolazine—Eye disorder—Methotrexate—testicular cancer	0.00112	0.00136	CcSEcCtD
Ranolazine—Tinnitus—Methotrexate—testicular cancer	0.00112	0.00136	CcSEcCtD
Ranolazine—Hypoaesthesia—Epirubicin—testicular cancer	0.00112	0.00136	CcSEcCtD
Ranolazine—Asthenia—Cisplatin—testicular cancer	0.00111	0.00135	CcSEcCtD
Ranolazine—Cardiac disorder—Methotrexate—testicular cancer	0.00111	0.00135	CcSEcCtD
Ranolazine—Urinary tract disorder—Epirubicin—testicular cancer	0.00111	0.00135	CcSEcCtD
Ranolazine—Oedema peripheral—Epirubicin—testicular cancer	0.00111	0.00134	CcSEcCtD
Ranolazine—Haematuria—Doxorubicin—testicular cancer	0.0011	0.00134	CcSEcCtD
Ranolazine—Connective tissue disorder—Epirubicin—testicular cancer	0.0011	0.00134	CcSEcCtD
Ranolazine—Urethral disorder—Epirubicin—testicular cancer	0.0011	0.00134	CcSEcCtD
Ranolazine—Epistaxis—Doxorubicin—testicular cancer	0.00109	0.00132	CcSEcCtD
Ranolazine—Angiopathy—Methotrexate—testicular cancer	0.00109	0.00132	CcSEcCtD
Ranolazine—Visual impairment—Epirubicin—testicular cancer	0.00108	0.00131	CcSEcCtD
Ranolazine—Mediastinal disorder—Methotrexate—testicular cancer	0.00108	0.00131	CcSEcCtD
Ranolazine—Nausea—Ifosfamide—testicular cancer	0.00107	0.0013	CcSEcCtD
Ranolazine—Bradycardia—Doxorubicin—testicular cancer	0.00106	0.00128	CcSEcCtD
Ranolazine—Mental disorder—Methotrexate—testicular cancer	0.00105	0.00128	CcSEcCtD
Ranolazine—Eye disorder—Epirubicin—testicular cancer	0.00105	0.00127	CcSEcCtD
Ranolazine—Tinnitus—Epirubicin—testicular cancer	0.00105	0.00127	CcSEcCtD
Ranolazine—Malnutrition—Methotrexate—testicular cancer	0.00104	0.00127	CcSEcCtD
Ranolazine—Cardiac disorder—Epirubicin—testicular cancer	0.00104	0.00126	CcSEcCtD
Ranolazine—Hypoaesthesia—Doxorubicin—testicular cancer	0.00103	0.00125	CcSEcCtD
Ranolazine—Urinary tract disorder—Doxorubicin—testicular cancer	0.00103	0.00124	CcSEcCtD
Ranolazine—Oedema peripheral—Doxorubicin—testicular cancer	0.00102	0.00124	CcSEcCtD
Ranolazine—Asthenia—Etoposide—testicular cancer	0.00102	0.00124	CcSEcCtD
Ranolazine—Connective tissue disorder—Doxorubicin—testicular cancer	0.00102	0.00124	CcSEcCtD
Ranolazine—Angiopathy—Epirubicin—testicular cancer	0.00102	0.00124	CcSEcCtD
Ranolazine—Urethral disorder—Doxorubicin—testicular cancer	0.00102	0.00124	CcSEcCtD
Ranolazine—Mediastinal disorder—Epirubicin—testicular cancer	0.00101	0.00123	CcSEcCtD
Ranolazine—Pruritus—Etoposide—testicular cancer	0.00101	0.00122	CcSEcCtD
Ranolazine—Arrhythmia—Epirubicin—testicular cancer	0.001	0.00122	CcSEcCtD
Ranolazine—Visual impairment—Doxorubicin—testicular cancer	0.001	0.00121	CcSEcCtD
Ranolazine—Vomiting—Cisplatin—testicular cancer	0.000987	0.0012	CcSEcCtD
Ranolazine—Vision blurred—Methotrexate—testicular cancer	0.000984	0.00119	CcSEcCtD
Ranolazine—Mental disorder—Epirubicin—testicular cancer	0.000983	0.00119	CcSEcCtD
Ranolazine—Rash—Cisplatin—testicular cancer	0.000979	0.00119	CcSEcCtD
Ranolazine—Dermatitis—Cisplatin—testicular cancer	0.000978	0.00119	CcSEcCtD
Ranolazine—Malnutrition—Epirubicin—testicular cancer	0.000977	0.00119	CcSEcCtD
Ranolazine—Eye disorder—Doxorubicin—testicular cancer	0.00097	0.00118	CcSEcCtD
Ranolazine—Tinnitus—Doxorubicin—testicular cancer	0.000968	0.00118	CcSEcCtD
Ranolazine—Cardiac disorder—Doxorubicin—testicular cancer	0.000964	0.00117	CcSEcCtD
Ranolazine—Flatulence—Epirubicin—testicular cancer	0.000963	0.00117	CcSEcCtD
Ranolazine—Angiopathy—Doxorubicin—testicular cancer	0.000942	0.00114	CcSEcCtD
Ranolazine—Dizziness—Etoposide—testicular cancer	0.000941	0.00114	CcSEcCtD
Ranolazine—Muscle spasms—Epirubicin—testicular cancer	0.000939	0.00114	CcSEcCtD
Ranolazine—Vertigo—Methotrexate—testicular cancer	0.000938	0.00114	CcSEcCtD
Ranolazine—Mediastinal disorder—Doxorubicin—testicular cancer	0.000936	0.00114	CcSEcCtD
Ranolazine—Leukopenia—Methotrexate—testicular cancer	0.000934	0.00113	CcSEcCtD
Ranolazine—Arrhythmia—Doxorubicin—testicular cancer	0.000928	0.00113	CcSEcCtD
Ranolazine—Nausea—Cisplatin—testicular cancer	0.000922	0.00112	CcSEcCtD
Ranolazine—Vision blurred—Epirubicin—testicular cancer	0.000921	0.00112	CcSEcCtD
Ranolazine—Cough—Methotrexate—testicular cancer	0.000911	0.00111	CcSEcCtD
Ranolazine—Mental disorder—Doxorubicin—testicular cancer	0.00091	0.0011	CcSEcCtD
Ranolazine—Vomiting—Etoposide—testicular cancer	0.000904	0.0011	CcSEcCtD
Ranolazine—Malnutrition—Doxorubicin—testicular cancer	0.000904	0.0011	CcSEcCtD
Ranolazine—Rash—Etoposide—testicular cancer	0.000897	0.00109	CcSEcCtD
Ranolazine—Dermatitis—Etoposide—testicular cancer	0.000896	0.00109	CcSEcCtD
Ranolazine—Headache—Etoposide—testicular cancer	0.000891	0.00108	CcSEcCtD
Ranolazine—Flatulence—Doxorubicin—testicular cancer	0.000891	0.00108	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000883	0.00107	CcSEcCtD
Ranolazine—Vertigo—Epirubicin—testicular cancer	0.000878	0.00107	CcSEcCtD
Ranolazine—Syncope—Epirubicin—testicular cancer	0.000876	0.00106	CcSEcCtD
Ranolazine—Leukopenia—Epirubicin—testicular cancer	0.000875	0.00106	CcSEcCtD
Ranolazine—Muscle spasms—Doxorubicin—testicular cancer	0.000869	0.00106	CcSEcCtD
Ranolazine—Palpitations—Epirubicin—testicular cancer	0.000863	0.00105	CcSEcCtD
Ranolazine—Confusional state—Methotrexate—testicular cancer	0.000859	0.00104	CcSEcCtD
Ranolazine—Loss of consciousness—Epirubicin—testicular cancer	0.000859	0.00104	CcSEcCtD
Ranolazine—Cough—Epirubicin—testicular cancer	0.000853	0.00103	CcSEcCtD
Ranolazine—Vision blurred—Doxorubicin—testicular cancer	0.000852	0.00103	CcSEcCtD
Ranolazine—Nausea—Etoposide—testicular cancer	0.000845	0.00103	CcSEcCtD
Ranolazine—Nervous system disorder—Methotrexate—testicular cancer	0.000836	0.00101	CcSEcCtD
Ranolazine—Thrombocytopenia—Methotrexate—testicular cancer	0.000834	0.00101	CcSEcCtD
Ranolazine—Anxiety—Epirubicin—testicular cancer	0.000829	0.00101	CcSEcCtD
Ranolazine—Skin disorder—Methotrexate—testicular cancer	0.000828	0.001	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000826	0.001	CcSEcCtD
Ranolazine—Hyperhidrosis—Methotrexate—testicular cancer	0.000824	0.001	CcSEcCtD
Ranolazine—Dry mouth—Epirubicin—testicular cancer	0.000813	0.000988	CcSEcCtD
Ranolazine—Vertigo—Doxorubicin—testicular cancer	0.000812	0.000986	CcSEcCtD
Ranolazine—Anorexia—Methotrexate—testicular cancer	0.000812	0.000986	CcSEcCtD
Ranolazine—Syncope—Doxorubicin—testicular cancer	0.000811	0.000984	CcSEcCtD
Ranolazine—Leukopenia—Doxorubicin—testicular cancer	0.000809	0.000982	CcSEcCtD
Ranolazine—Confusional state—Epirubicin—testicular cancer	0.000804	0.000976	CcSEcCtD
Ranolazine—Palpitations—Doxorubicin—testicular cancer	0.000799	0.00097	CcSEcCtD
Ranolazine—Hypotension—Methotrexate—testicular cancer	0.000796	0.000966	CcSEcCtD
Ranolazine—Loss of consciousness—Doxorubicin—testicular cancer	0.000795	0.000965	CcSEcCtD
Ranolazine—Cough—Doxorubicin—testicular cancer	0.000789	0.000958	CcSEcCtD
Ranolazine—Shock—Epirubicin—testicular cancer	0.000784	0.000952	CcSEcCtD
Ranolazine—Nervous system disorder—Epirubicin—testicular cancer	0.000782	0.000949	CcSEcCtD
Ranolazine—Thrombocytopenia—Epirubicin—testicular cancer	0.000781	0.000948	CcSEcCtD
Ranolazine—Skin disorder—Epirubicin—testicular cancer	0.000774	0.00094	CcSEcCtD
Ranolazine—Hyperhidrosis—Epirubicin—testicular cancer	0.000771	0.000936	CcSEcCtD
Ranolazine—Insomnia—Methotrexate—testicular cancer	0.000771	0.000935	CcSEcCtD
Ranolazine—Anxiety—Doxorubicin—testicular cancer	0.000767	0.000931	CcSEcCtD
Ranolazine—Paraesthesia—Methotrexate—testicular cancer	0.000765	0.000929	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000764	0.000928	CcSEcCtD
Ranolazine—Anorexia—Epirubicin—testicular cancer	0.00076	0.000923	CcSEcCtD
Ranolazine—Dyspnoea—Methotrexate—testicular cancer	0.00076	0.000922	CcSEcCtD
Ranolazine—Somnolence—Methotrexate—testicular cancer	0.000757	0.00092	CcSEcCtD
Ranolazine—Dry mouth—Doxorubicin—testicular cancer	0.000753	0.000914	CcSEcCtD
Ranolazine—Dyspepsia—Methotrexate—testicular cancer	0.00075	0.00091	CcSEcCtD
Ranolazine—Hypotension—Epirubicin—testicular cancer	0.000745	0.000904	CcSEcCtD
Ranolazine—Confusional state—Doxorubicin—testicular cancer	0.000744	0.000903	CcSEcCtD
Ranolazine—Decreased appetite—Methotrexate—testicular cancer	0.000741	0.000899	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000736	0.000893	CcSEcCtD
Ranolazine—Fatigue—Methotrexate—testicular cancer	0.000735	0.000892	CcSEcCtD
Ranolazine—Shock—Doxorubicin—testicular cancer	0.000726	0.000881	CcSEcCtD
Ranolazine—Nervous system disorder—Doxorubicin—testicular cancer	0.000724	0.000878	CcSEcCtD
Ranolazine—Thrombocytopenia—Doxorubicin—testicular cancer	0.000722	0.000877	CcSEcCtD
Ranolazine—Insomnia—Epirubicin—testicular cancer	0.000721	0.000875	CcSEcCtD
Ranolazine—Skin disorder—Doxorubicin—testicular cancer	0.000717	0.00087	CcSEcCtD
Ranolazine—Paraesthesia—Epirubicin—testicular cancer	0.000716	0.000869	CcSEcCtD
Ranolazine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000713	0.000866	CcSEcCtD
Ranolazine—Dyspnoea—Epirubicin—testicular cancer	0.000711	0.000863	CcSEcCtD
Ranolazine—Somnolence—Epirubicin—testicular cancer	0.000709	0.000861	CcSEcCtD
Ranolazine—Anorexia—Doxorubicin—testicular cancer	0.000703	0.000854	CcSEcCtD
Ranolazine—Feeling abnormal—Methotrexate—testicular cancer	0.000702	0.000852	CcSEcCtD
Ranolazine—Dyspepsia—Epirubicin—testicular cancer	0.000702	0.000852	CcSEcCtD
Ranolazine—Gastrointestinal pain—Methotrexate—testicular cancer	0.000697	0.000846	CcSEcCtD
Ranolazine—Decreased appetite—Epirubicin—testicular cancer	0.000693	0.000841	CcSEcCtD
Ranolazine—Hypotension—Doxorubicin—testicular cancer	0.000689	0.000837	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000688	0.000836	CcSEcCtD
Ranolazine—Fatigue—Epirubicin—testicular cancer	0.000687	0.000835	CcSEcCtD
Ranolazine—Constipation—Epirubicin—testicular cancer	0.000682	0.000828	CcSEcCtD
Ranolazine—Urticaria—Methotrexate—testicular cancer	0.000677	0.000822	CcSEcCtD
Ranolazine—Abdominal pain—Methotrexate—testicular cancer	0.000674	0.000818	CcSEcCtD
Ranolazine—Insomnia—Doxorubicin—testicular cancer	0.000667	0.00081	CcSEcCtD
Ranolazine—Paraesthesia—Doxorubicin—testicular cancer	0.000662	0.000804	CcSEcCtD
Ranolazine—Dyspnoea—Doxorubicin—testicular cancer	0.000658	0.000798	CcSEcCtD
Ranolazine—Feeling abnormal—Epirubicin—testicular cancer	0.000657	0.000798	CcSEcCtD
Ranolazine—Somnolence—Doxorubicin—testicular cancer	0.000656	0.000796	CcSEcCtD
Ranolazine—Gastrointestinal pain—Epirubicin—testicular cancer	0.000652	0.000792	CcSEcCtD
Ranolazine—Dyspepsia—Doxorubicin—testicular cancer	0.000649	0.000788	CcSEcCtD
Ranolazine—Decreased appetite—Doxorubicin—testicular cancer	0.000641	0.000779	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000637	0.000773	CcSEcCtD
Ranolazine—Fatigue—Doxorubicin—testicular cancer	0.000636	0.000772	CcSEcCtD
Ranolazine—Urticaria—Epirubicin—testicular cancer	0.000633	0.000769	CcSEcCtD
Ranolazine—Constipation—Doxorubicin—testicular cancer	0.000631	0.000766	CcSEcCtD
Ranolazine—Abdominal pain—Epirubicin—testicular cancer	0.00063	0.000765	CcSEcCtD
Ranolazine—Asthenia—Methotrexate—testicular cancer	0.000611	0.000742	CcSEcCtD
Ranolazine—Feeling abnormal—Doxorubicin—testicular cancer	0.000608	0.000738	CcSEcCtD
Ranolazine—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000603	0.000732	CcSEcCtD
Ranolazine—Pruritus—Methotrexate—testicular cancer	0.000603	0.000732	CcSEcCtD
Ranolazine—Urticaria—Doxorubicin—testicular cancer	0.000586	0.000711	CcSEcCtD
Ranolazine—Abdominal pain—Doxorubicin—testicular cancer	0.000583	0.000708	CcSEcCtD
Ranolazine—Asthenia—Epirubicin—testicular cancer	0.000572	0.000694	CcSEcCtD
Ranolazine—Pruritus—Epirubicin—testicular cancer	0.000564	0.000685	CcSEcCtD
Ranolazine—Dizziness—Methotrexate—testicular cancer	0.000563	0.000684	CcSEcCtD
Ranolazine—Vomiting—Methotrexate—testicular cancer	0.000542	0.000658	CcSEcCtD
Ranolazine—Rash—Methotrexate—testicular cancer	0.000537	0.000652	CcSEcCtD
Ranolazine—Dermatitis—Methotrexate—testicular cancer	0.000537	0.000652	CcSEcCtD
Ranolazine—Headache—Methotrexate—testicular cancer	0.000534	0.000648	CcSEcCtD
Ranolazine—Asthenia—Doxorubicin—testicular cancer	0.000529	0.000643	CcSEcCtD
Ranolazine—Dizziness—Epirubicin—testicular cancer	0.000527	0.00064	CcSEcCtD
Ranolazine—Pruritus—Doxorubicin—testicular cancer	0.000522	0.000634	CcSEcCtD
Ranolazine—Vomiting—Epirubicin—testicular cancer	0.000507	0.000615	CcSEcCtD
Ranolazine—Nausea—Methotrexate—testicular cancer	0.000506	0.000614	CcSEcCtD
Ranolazine—Rash—Epirubicin—testicular cancer	0.000503	0.00061	CcSEcCtD
Ranolazine—Dermatitis—Epirubicin—testicular cancer	0.000502	0.00061	CcSEcCtD
Ranolazine—Headache—Epirubicin—testicular cancer	0.0005	0.000606	CcSEcCtD
Ranolazine—Dizziness—Doxorubicin—testicular cancer	0.000488	0.000592	CcSEcCtD
Ranolazine—Nausea—Epirubicin—testicular cancer	0.000474	0.000575	CcSEcCtD
Ranolazine—Vomiting—Doxorubicin—testicular cancer	0.000469	0.000569	CcSEcCtD
Ranolazine—Rash—Doxorubicin—testicular cancer	0.000465	0.000565	CcSEcCtD
Ranolazine—Dermatitis—Doxorubicin—testicular cancer	0.000465	0.000564	CcSEcCtD
Ranolazine—Headache—Doxorubicin—testicular cancer	0.000462	0.000561	CcSEcCtD
Ranolazine—Nausea—Doxorubicin—testicular cancer	0.000438	0.000532	CcSEcCtD
